Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full News1.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
2.
Triplet Could Become a New Standard in Tough-to-Treat CLL
3.
Dasatinib Fails to Improve Outcomes in CBF-AML
4.
Financial hardship common in patients with cancer
5.
New study links air pollution with higher rates of head and neck cancer
1.
Remote Hematology Follow-Up: Advancements, Clinical Implications, and Future Directions
2.
Red Blood Cell Aging and Clinical Implications
3.
Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation
4.
Tumor Evolution Under Treatment Pressure: Real-Time Tracking of Resistance and Clonal Selection
5.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Cancer Care: From Awareness to Recovery
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
Efficient Management of First line ALK-rearranged NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation